🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
3.310
-0.070 (-2.07%)
Nov 18, 2026, 10:50 AM EST - Market open

Aclaris Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
6.47.8318.7231.2529.56.64
Other Revenue
----0.260.12
6.47.8318.7231.2529.756.76
Revenue Growth
-59.34%-58.19%-40.09%5.03%340.05%4.30%
Cost of Revenue
72.459.9349.04114.2589.7748.53
Gross Profit
-66-52.1-30.32-83-60.02-41.77
Selling, General & Admin
24.4121.9722.231.5125.1323.62
Operating Expenses
24.4121.9722.231.5125.1323.62
Operating Income
-90.41-74.08-52.53-114.51-85.15-65.38
Interest & Investment Income
6.767.647.958.51--
Other Non Operating Income (Expenses)
4.123.821.91-2.95-1.14
EBT Excluding Unusual Items
-79.53-62.62-42.66-106-82.21-66.53
Merger & Restructuring Charges
----3.12--
Other Unusual Items
-0.1-2.3-2.526.9-4.7-24.34
Pretax Income
-79.63-64.92-132.07-88.85-86.91-90.87
Income Tax Expense
----0.37--
Earnings From Continuing Operations
-79.63-64.92-132.07-88.48-86.91-90.87
Net Income
-79.63-64.92-132.07-88.48-86.91-90.87
Net Income to Common
-79.63-64.92-132.07-88.48-86.91-90.87
Net Income Growth
------
Shares Outstanding (Basic)
13612377706557
Shares Outstanding (Diluted)
13612377706557
Shares Change
17.46%58.56%10.73%7.05%14.95%33.36%
EPS (Basic)
-0.59-0.53-1.71-1.27-1.33-1.60
EPS (Diluted)
-0.59-0.53-1.71-1.27-1.33-1.60
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-75.32-47.22-20.2-79.63-68.17-52.44
Free Cash Flow Per Share
-0.55-0.39-0.26-1.14-1.04-0.92
Gross Margin
---161.99%-265.60%-201.74%-
Operating Margin
-1412.40%-946.52%-280.59%-366.44%-286.21%-967.08%
Profit Margin
-1244.09%-829.58%-705.48%-283.15%-292.11%-1343.96%
Free Cash Flow Margin
-1176.61%-603.42%-107.89%-254.84%-229.13%-775.65%
EBITDA
--74.04-52.22-114.45--65.06
EBITDA Margin
---278.95%---
D&A For EBITDA
-0.040.310.06-0.32
EBIT
-90.41-74.08-52.53-114.51-85.15-65.38
EBIT Margin
---280.59%--286.21%-
Revenue as Reported
6.47.8318.7231.2529.756.76
SEC Filings: 10-K · 10-Q